Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 3141303 trials

Genome&Company

Official website

A drug developer building ADC and immuno-oncology pipelines on its GNOCLE™ platform, alongside microbiome cosmetics and CDMO businesses.

As of 2026-10-10, Genome&Company has 27 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2015 and listed on KOSDAQ in 2020, Genome & Company is a drug development specialist built on its GNOCLE™ platform, advancing ADC and immuno-oncology pipelines targeting novel antigens. Its novel-target immuno-oncology candidate GENA-104 (EP0089) was licensed to UK-based Ellipses Pharma Limited in February 2025, and its novel-target ADC antibody Debio 0633 was licensed to Debiopharm in June 2024, while the company also runs a consumer business through its microbiome skincare brand UIQ and probiotic IMMUNOVA GEN001. It additionally operates a CDMO business through List Biological Laboratories, a US microbiome CDMO acquired in September 2021, with revenue drawn from licensing income, cosmetics sales, and biopharmaceutical contract manufacturing.

Products & technology

  • GENA-104 (EP0089)Novel-target (CNTN4) immuno-oncology antibody candidate
  • Debio 0633Novel-target antibody for ADC development
  • GENA-104 ADCCNTN4-targeting antibody-drug conjugate candidate
  • UIQMicrobiome skincare brand containing Cutibiome, Reliefbiome, Rejubiome ingredients
  • IMMUNOVA GEN001Medical-grade probiotic based on strain GEN-001

Clinical trials

data.go.kr

3 MFDS clinical trial authorisations · 2020–2022 (Phase 2 2 · Phase 1 1)

  • Phase 2GEN-0012022-11-07

    8 trial sites

  • Phase 2GEN-0012021-10-08

    5 trial sites

  • Phase 1GEN-0012020-11-09

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

GENA-104(EP0089) · 면역항암(CNTN4 표적) · 라이선시(엘립시스 파마) 임상1상 · IND approved in Korea Jan 2024; published in Science Immunology Oct 2024; presented at AACR 2025

Debio 0633 · ADC(신규타깃) · 디바이오팜 개발 중 · Combined with Debiopharm's proprietary Multilink technology for ADC development

GENA-104 ADC · CNTN4 표적 ADC · 전임상(PDX 평가 중) · Exatecan (Topo1 inhibitor)-conjugated candidate showed antitumor efficacy in mouse CDX model

GENA-120 · 신규타깃(ITGB4) ADC · Source text is truncated mid-sentence; details unavailable

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 17 more publications

Patents

KIPRIS · applicant-matched
Show 32 more patents

AI reads

MAA server logs · IP-verified
73
Times AI engines pulled Genome&Company's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

7
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

66
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

16
live 3
Last 7 days
62
live 7
Last 30 days
73
live 7
All time
  • OpenAIChatGPT-Userlive7
  • OpenAIOAI-SearchBot59
  • PerplexityPerplexityBot4
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Genome&Company and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition